MannKind (MNKD) Stock Still Looks Cheap On Fair Value And Sales
MannKind stock has fallen 29.5% year to date, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market based valuation multiples currently point to the shares trading at a discount to their assessed worth.
- The near 30% year to date decline suggests sentiment has weakened, even as valuation models indicate potential upside from current levels.
- FDA approval of Furoscix ReadyFlow may support expectations for MannKind's future revenue, while the recent US$50 million private placement highlights the ongoing need to fund growth and associated obligations.
- MannKind scores 3 out of 6 on Simply Wall St's broader valuation checks, which presents a mixed picture rather than a clear bargain or clear overvaluation, and you can see the breakdown here.
The key question now is whether MannKind's recent share price weakness already reflects the main risks around execution and funding, or if the current discount to intrinsic value and multiples still misprices the stock.
Find out why MannKind's -0.3% return over the last year is lagging behind its peers.
Is MannKind Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model for MannKind uses projected future free cash flows and discounts them back to today. MannKind currently reports latest twelve month free cash flow of a loss of about $1.27 million, and the model assumes recovering and then growing cash flows over time as the business scales.
Based on these projections, the DCF output points to an intrinsic value of about $4.92 per share, which is above the recent market price and implies the stock is 19.7% undervalued. The FDA approval of Furoscix ReadyFlow is a potential growth driver, and the ongoing funding needs highlighted by the recent US$50 million private placement help explain why the market currently prices MannKind below the cash flow based estimate.
On balance, MannKind stock currently appears undervalued relative to its Discounted Cash Flow estimate.
Our Discounted Cash Flow (DCF) analysis suggests MannKind is undervalued by 19.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.
Does MannKind Look Undervalued on Sales?
P/S is often a useful cross check for MannKind because revenue is reported even while free cash flow is still negative. MannKind currently trades on a P/S of about 3.4x, compared with the Biotechs industry average of roughly 11.0x and a peer group average near 2.9x.
The tailored fair P/S ratio for MannKind is estimated at about 5.1x. This incorporates factors such as the company’s growth profile, margins, scale and risk level, and it sits above both the current P/S and the simple peer average. The gap between MannKind’s current multiple and this fair ratio indicates that the stock is pricing in more caution than the model implies.
On this P/S yardstick, MannKind stock appears inexpensive relative to what the fair multiple suggests.
See what the numbers say about this price — find out in our valuation breakdown.
The MannKind Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for MannKind pick up where the DCF and P/S discussion leaves off and describe what kind of future for MannKind's growth, margins and earnings would correspond to a much higher or much lower share price than today. Each one links its number to a clear view on how MannKind's growth, profitability and risks could develop, providing a reference point you can revisit as new information appears.
One of the top community narratives on MannKind: 48% undervalued
"Afrezza's pediatric approval is a key milestone that could expand the potential user base over time and reshape how investors view MannKind's commercial story…"
Read one of the top narratives on MannKind
Do you think there's more to the story for MannKind? Head over to our Community to see what others are saying!
The Bottom Line
MannKind looks undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the tailored P/S multiple, even though the broader valuation checks sit in the middle of the pack. That mix suggests the stock screens as cheap, but not without strings attached given ongoing funding needs and execution risks. The key question is whether MannKind can translate its product approvals and pipeline into the cash flow and revenue profile that those valuation models imply. The crux for investors from here is whether current caution in the share price reflects a genuine value opportunity or a fair discount to compensate for those risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com